Risks of Mild Calcified Plaques of the Abdominal Aorta

Cardiovascular Risk Profile

Mild calcified plaques in the abdominal aorta are relatively stable lesions with lower embolic risk compared to non-calcified plaques, but they serve as important markers of systemic atherosclerosis and increased cardiovascular risk, according to the American Heart Association 1, 2
Calcified plaques are more stable and less likely to result in embolic syndromes compared to non-calcified plaques, as stated by the American College of Cardiology 1, 2

No routine revascularization is indicated for asymptomatic mild stenosis, as it does not benefit from intervention and may increase procedural risks, as recommended by the European Society of Cardiology 3
Embolic risk is lower than non-calcified disease, while aortic arch plaques ≥4mm carry a relative risk of 3.8 for new ischemic stroke, according to the American Heart Association 1, 2

Intensive cardiovascular risk factor modification is the cornerstone of management for mild calcified abdominal aortic plaques, as stated by the European Society of Cardiology 4, 3

Intensive lipid management to LDL-C <1.4 mmol/L (<55 mg/dL) is recommended to prevent progression of atheromatous disease, as recommended by the European Atherosclerosis Society 4, 3
Single antiplatelet therapy (aspirin or clopidogrel) should be used if there is evidence of prior embolic events or concomitant coronary disease, according to the American College of Cardiology 4, 5, 3
Anticoagulation or dual antiplatelet therapy are NOT recommended for aortic plaques as they provide no benefit and significantly increase bleeding risk, as stated by the European Society of Cardiology 4, 5, 3
Blood pressure control targeting <140/90 mmHg for chronic management, with consideration of beta-blockers to reduce aortic wall stress, as recommended by the European Society of Hypertension 3

Duplex ultrasound every 3 years is appropriate for mild atheromatous changes without aneurysmal dilation, as recommended by the European Society of Cardiology 3
Annual follow-up to assess cardiovascular risk factors and treatment compliance is essential, according to the European Society of Cardiology 4, 3
If aortic diameter is ≥25mm and <30mm, surveillance every 4 years should be considered in patients with life expectancy >2 years, as stated by the European Society of Cardiology 3
Cardiovascular computed tomography or magnetic resonance imaging should be used if duplex ultrasound does not allow adequate measurement, as recommended by the European Society of Cardiology 3

Do not assume calcification eliminates all risk, as calcified lesions still indicate systemic atherosclerotic burden requiring aggressive risk factor modification, according to the American Heart Association 1, 2
Avoid fluoroquinolones unless there is a compelling indication with no alternative, as they increase risk of aortic complications, as stated by the European Society of Cardiology 4, 3
Do not overlook assessment of the entire aorta, as evaluation of the thoracic aorta and branch vessels is warranted given the high prevalence of multi-site disease, according to the European Society of Cardiology 4
Recognize that negative chest X-ray should not delay definitive imaging in patients at high risk for aortic complications, as recommended by the European Society of Cardiology 3